---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-049581"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T04:32:55.085972+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BrainStorm Q1 net loss $2.9M; advances NurOwn Phase 3b trial with IND amendment

## Summary
- Net loss of $2.9M ($0.45/share) improved vs $3.4M ($0.75/share) in Q1 2024.
- Cash, equivalents restricted cash $1.8M at March 31, 2025; R&D $1.3M, G&A $1.8M.
- Submitted IND amendment for Phase 3b NurOwn trial (ENDURANCE) targeting ~200 early ALS patients with SPA.
- Trial listed on ClinicalTrials.gov (NCT06973629) with 15 clinical sites; data at ISCT and ALS Summit.
- Conference call rescheduled to May 19, 2025 at 8:30 AM ET.

## SEC filing metadata
- accession: 0001104659-25-049581
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465925049581/0001104659-25-049581-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465925049581/tm2515198d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-049581
- JSON: https://secwatch.observer/filing/0001104659-25-049581.json
- Plain text: https://secwatch.observer/filing/0001104659-25-049581.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.